Doxycycline Monohydrate 25 mg (5mL) Oral Suspension Under Fasting Conditions
Status:
Completed
Trial end date:
2006-10-01
Target enrollment:
Participant gender:
Summary
The objective of this single-dose, open-label, randomized, two-period crossover study was to
compare the rate of absorption and oral bioavailability of a test formulation of doxycycline
monohydrate 1 x 25 mg (5mL) oral suspension manufactured by IVAX Pharmaceuticals, Inc. and
distributed by TEVA Pharmaceuticals USA to an equivalent oral dose of the commercially
available reference product, Vibramycin Monohydrate® manufactured by Pfizer, Inc. following
an overnight fast of at least 10 hours.